BioCentury
ARTICLE | Company News

Bristol-Myers, Sanofi deal

October 8, 2012 7:00 AM UTC

Sanofi and Bristol-Myers restructured a 1993 co-promotion deal for three cardiovascular drugs - Plavix clopidogrel, Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide - following the drugs' loss of exclusivity in the U.S. this year. Effective Jan. 1, 2013, Bristol-Myers will return to Sanofi worldwide rights to the drugs, excluding rights for Plavix in the U.S. and Puerto Rico, where Bristol-Myers will retain rights through December 2019. Bristol-Myers will now receive royalties on Sanofi's sales of branded and unbranded Plavix, Avapro and Avalide through 2018, plus a terminal $200 million payment from Sanofi in December 2018. The partners said the amended deal also resolves ongoing disputes between the companies, including the one-time payment of $80 million by Bristol-Myers to Sanofi for Avalide supply disruption in the U.S. in 2011. Bristol-Myers declined to disclose details. ...